Telomir Pharmaceuticals, Inc. Common Stock (TELO) Financials

$4.23

south_east
-$0.29 (-6.42%)
Day's range
$4.23
Day's range
$4.62

TELO Income statement / Annual

Last year (2024), Telomir Pharmaceuticals, Inc. Common Stock's total revenue was $0.00, and the percentage change from the previous year is not available. In 2024, Telomir Pharmaceuticals, Inc. Common Stock's net income was -$16.53 M. See Telomir Pharmaceuticals, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Operating Revenue $0.00 $0.00 $0.00 $0.00
Cost of Revenue $0.00 $3.94 M $0.00 $0.00
Gross Profit $0.00 -$3.94 M $0.00 $0.00
Gross Profit Ratio 0 0 0 0
Research and Development Expenses $2.24 M $1.57 M $833,206.00 $126,492.00
General & Administrative Expenses $9.64 M $600,192.00 $20,941.00 $11,639.00
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $9.64 M $600,192.00 $20,941.00 $11,639.00
Other Expenses $0.00 $0.00 $0.00 $0.00
Operating Expenses $11.87 M $3.94 M $854,147.00 $138,131.00
Cost And Expenses $0.00 $3.94 M $854,147.00 $138,131.00
Interest Income $48,000.00 $0.00 $0.00 $0.00
Interest Expense -$4.34 M $1.64 M $0.00 $0.00
Depreciation & Amortization $0.00 -$7.49 M $854,147.00 $138,131.00
EBITDA $0.00 -$11.43 M -$854,147.00 -$138,131.00
EBITDA Ratio 0 0 0 0
Operating Income Ratio 0 0 0 0
Total Other Income/Expenses Net $0.00 -$9.13 M $0.00 $0.00
Income Before Tax -$16.53 M -$13.07 M -$854,147.00 -$138,131.00
Income Before Tax Ratio 0 0 0 0
Income Tax Expense -$16.53 M $0.00 -$854,144.00 -$138,132.00
Net Income -$16.53 M -$13.07 M -$854,147.00 -$138,131.00
Net Income Ratio 0 0 0 0
EPS -0.56 -0.44 -0.0288 -0.0047
EPS Diluted -0.56 -0.44 -0.0288 -0.0047
Weighted Average Shares Out $29.54 M $29.61 M $29.61 M $29.61 M
Weighted Average Shares Out Diluted $29.54 M $29.61 M $29.61 M $29.61 M
Link